Pfizer Inc. (NYSE:PFE) Shares Bought by Kennedy Capital Management LLC

Kennedy Capital Management LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 24.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 206,886 shares of the biopharmaceutical company’s stock after buying an additional 40,193 shares during the quarter. Kennedy Capital Management LLC’s holdings in Pfizer were worth $5,489,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank purchased a new stake in shares of Pfizer in the fourth quarter valued at about $2,328,986,000. Charles Schwab Investment Management Inc. raised its holdings in Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Pfizer during the 4th quarter valued at $274,694,000. Massachusetts Financial Services Co. MA grew its stake in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after buying an additional 5,350,381 shares in the last quarter. Finally, APG Asset Management N.V. lifted its position in shares of Pfizer by 1,106.0% during the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company’s stock worth $143,967,000 after purchasing an additional 5,153,257 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Up 1.4 %

Pfizer stock opened at $21.89 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $124.14 billion, a P/E ratio of 15.52, a P/E/G ratio of 0.64 and a beta of 0.67. The company’s 50-day moving average price is $25.25 and its two-hundred day moving average price is $26.40. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the firm earned $0.10 EPS. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday. UBS Group lowered their target price on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research note on Tuesday. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Citigroup reissued a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.07.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.